<DOC>
	<DOCNO>NCT02129478</DOCNO>
	<brief_summary>Olanzapine license use adult Canada teens US mental illness . It also often used management mental illness child . This study describe feasibility give olanzapine plus usual medication prevent chemotherapy induce nausea vomit ( CINV ) 15 child age 4 18 year . What do already ? - In adult cancer patient , olanzapine improve control CINV . None adult study experienced serious side effect olanzapine . What study study conduct ? - On day chemotherapy give , olanzapine give 15 child along regular medication prevent CINV . Investigators study child one chemotherapy cycle . Participants ' blood sugar , liver function test ( AST ALT ) , prolactin triglyceride level , blood pressure , weight , mood behavior time receive olanzapine evaluate see change . Investigators record anything serious happen child receive olanzapine . If child stop olanzapine early decides decrease dose , reason record . Each child guardian record nausea severity time vomit retch day receive chemotherapy 8 day afterwards . How study help ? - This study help investigator decide feasible conduct large study find olanzapine improves CINV control child . If child able take olanzapine set study without significant side effect , large study would feasible .</brief_summary>
	<brief_title>Olanzapine Prevention Chemotherapy-induced Nausea Vomiting Children : A Multi-Centre Feasibility Study</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>4 18 year old Englishspeaking Englishspeaking parent/guardian Have minimum cognitive ability 4 year old assess health care professional Scheduled receive moderately highly emetogenic chemotherapy assess use Pediatric Oncology Group Ontario Guideline emetogenicity Classification Antineoplastic Agents Children least one day course chemotherapy Scheduled receive either ondansetron , granisetron palonosetron without dexamethason schedule basis order patient 's clinical team per usual antiemetic standard care Weigh least 14kg Have serum total bilirubin ≤ 3 mg/dl ( 50 µmol/L ) , ALT AST ≤ 3x upper limit normal age Consent use adequate contraception remain abstinent day olanzapine give 5 day afterward childbearing potential Brain tumor patient Have treatment within 14 day prior study enrollment olanzapine 30 day prior study enrollment another antipsychotic agent Planned receive amifostine , CYP1A2 inducers inhibitor , antipsychotic agent quinolone antibiotic receive olanzapine ; Have uncontrolled hypertension Receive antiphychotic agent , amifostine , citalopram , CYP1A2 inducers inhibitor , quinolone antibiotic receive olanzapine Receive scopolamine patch , phenothiazine , acupressure acupuncture study period Planned receive antiemetic agent dexamethasone , ondansetron , granisetron , palonosetron , aprepitant fosaprepitant schedule basis Have history neuroleptic malignant syndrome , seizure disorder , hypersensitivity olanzapine , cardiac arrhythmia include prolonged QT , low leave ventricular ejection fraction , history uncontrolled diabetes mellitus Are pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>olanzapine</keyword>
	<keyword>pediatrics</keyword>
	<keyword>chemotherapy-induced nausea</keyword>
	<keyword>chemotherapy-induced vomiting</keyword>
</DOC>